Intercellular trafficking of the nuclear oncoprotein DEK

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 17, 2013, Pages 6847-6852

  Saha, Anjan K ^a   Kappes, Ferdinand ^a   Mundade, Amruta ^b   Deutzmann, Anja ^c   Rosmarin, David M ^d,f   Legendre, Maureen ^a   Chatain, Nicolas ^b   Al Obaidi, Zeina ^a   Adams, Barbara S ^a   Ploegh, Hidde L ^d   Ferrando May, Elisa ^c   Mor Vaknin, Nirit ^a   Markovitz, David M ^a,e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF KONSTANZ   (Germany)

^d WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f TUFTS MEDICAL CENTER   (United States)

Author keywords

Autoimmunity; Cancer; Cellular biology; Juvenile arthritis

Indexed keywords

HEPARAN SULFATE; ONCOPROTEIN; ONCOPROTEIN DEK; UNCLASSIFIED DRUG;

ARTICLE; DNA REPAIR; HUMAN; HUMAN CELL; MACROPHAGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SYNOVIUM;

CELL FRACTIONATION; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA REPAIR; HELA CELLS; HETEROCHROMATIN; HISTONES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MICROSCOPY, FLUORESCENCE; ONCOGENE PROTEINS; PARACRINE COMMUNICATION; PROTEIN TRANSPORT; RNA, SMALL INTERFERING;

EID: 84876886900     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1220751110     Document Type: Article

References (37)

1. von Lindern M, Poustka A, Lerach H, Grosveld G (1990) The (6;9) chromosome trans-location, associated with a specific subtype of acute nonlymphocytic leukemia, leads to aberrant transcription of a target gene on 9q34. Mol Cell Biol 10(8):4016-4026.
2. von Lindern M, et al. (1992) The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 12(4): 1687-1697.
3. Kappes F, et al. (2011) The DEK oncoprotein is a Su(var) that is essential to hetero-chromatin integrity. Genes Dev 25(7):673-678.
4. McGarvey T, et al. (2000) The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon-product complexes. J Cell Biol 150(2): 309-320.
5. Soares LM, Zanier K, Mackereth C, Sattler M, Valcárcel J (2006) Intron removal requires proofreading of U2AF/3′ splice site recognition by DEK. Science 312(5782): 1961-1965.
6. Fu GK, Grosveld G, Markovitz DM (1997) DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer. Proc Natl Acad Sci USA 94(5):1811-1815.
7. Adams BS, et al. (2003) DEK binding to class II MHC Y-box sequences is gene-and allele-specific. Arthritis Res Ther 5(4):R226-R233.
8. Khodadoust MS, et al. (2009) Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 69(16):6405-6413.
9. Kappes F, et al. (2008) DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol Cell Biol 28(10):3245-3257.
10. Kavanaugh GM, et al. (2011) The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res 39(17):7465-7476.
11. Alexiadis V, et al. (2000) The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chro-matin-specific manner. Genes Dev 14(11):1308-1312.
12. Broxmeyer HE, et al. (2011) DEK regulates hematopoietic stem engraftment and progenitor cell proliferation. Stem Cells Dev 21(9):1449-1454.
13. Koleva RI, et al. (2012) C/EBPalpha and DEK coordinately regulate myeloid differentiation. Blood 119(21):4878-4888.
14. Wise-Draper TM, et al. (2006) Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol 26(20):7506-7519.
15. Wise-Draper TM, et al. (2005) The human DEK proto-oncogene is a senescence inhibitor and an up-regulated target of high-risk human papillomavirus E7. J Virol 79(22):14309-14317.
16. Cheung TH, et al. (2012) Maintenance of muscle stem-cell quiescence by microRNA-489. Nature 482(7386):524-528.
17. Kondoh N, et al. (1999) Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 59(19):4990-4996.
18. Kroes RA, et al. (2000) The identification of novel therapeutic targets for the treatment of malignant brain tumors. Cancer Lett 156(2):191-198.
19. Kappes F, et al. (2011) DEK expression in melanocytic lesions. Hum Pathol 42(7): 932-938.
20. Evans AJ, et al. (2004) Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction. Am J Pathol 164(1):285-293.
21. Grasemann C, et al. (2005) Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene 24(42):6441-6449.
22. Orlic M, Spencer CE, Wang L, Gallie BL (2006) Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer 45(1):72-82.
23. Privette Vinnedge LM, et al. (2011) The human DEK oncogene stimulates p-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene 30(24): 2741-2752.
24. + T-cell large granular lymphocyte leukemia. IntJ Cancer 108(6):845-851.
25. Babaei-Jadidi R, et al. (2011) FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J Exp Med 208(2):295-312.
26. Dong X, et al. (1998) Autoantibodies to DEK oncoprotein in a patient with systemic lupus erythematosus and sarcoidosis. Arthritis Rheum 41(8):1505-1510.
27. Mor-Vaknin N, et al. (2011) DEK in the synovium of patients with juvenile idiopathic arthritis: Characterization of DEK antibodies and posttranslational modification of the DEK autoantigen. Arthritis Rheum 63(2):556-567.
28. Mor-Vaknin N, et al. (2006) The DEK nuclear autoantigen is a secreted chemotactic factor. Mol Cell Biol 26(24):9484-9496.
29. Yang D, et al. (2007) High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 81(1):59-66.
30. Wang Y, et al. (2006) Cellular uptake of exogenous human PDCD5 protein. J Biol Chem 281(34):24803-24817.
31. Console S, Marty C, García-Echeverría C, Schwendener R, Ballmer-Hofer K (2003) Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 278(37):35109-35114.
32. Cronican JJ, et al. (2011) A class of human proteins that deliver functional proteins into mammalian cells in vitro and in vivo. Chem Biol 18(7):833-838.
33. Rosmarin DM, et al. (2012) Attachment of Chlamydia trachomatis L2 to host cells requires sulfation. Proc Natl Acad Sci USA 109(25):10059-10064.
34. Carette JE, et al. (2011) Ebola virus entry requires the cholesterol transporter Nie-mann-Pick C1. Nature 477(7364):340-343.
35. Kappes F, Burger K, Baack M, Fackelmayer FO, Gruss C (2001) Subcellular localization of the human proto-oncogene protein DEK. J Biol Chem 276(28):26317-26323.
36. Preisach C, Burkhardt H, Decker R, Schmidt-Thieme L (2008) Data analysis, machine learning and applications. Proceedings of the 31st Annual Conference of the Ge-sellschaft für Klassifikation e.V., Albert-Ludwigs-Universität Freiburg, March 7-9, 2007 (Springer, Berlin).
37. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273(10): 5858-5868.